Latest News
Arrevus Closes Acquisition of Fusidic Acid from Melinta Therapeutics
Friday 08 February 2019

8 February 2019 - US-based biotechnology company Arrevus Inc. has completed the acquisition of fusidic acid from Melinta Therapeutics, the company said.

Arrevus said it is now better positioned to advance its pipeline into clinical use for patients with serious bacterial infections where there is substantial unmet need.

Melinta Therapeutics is a commercial-stage company dedicated to developing and commercializing novel antibiotics to treat serious bacterial infections and currently has four FDA-approved antibiotics.

On December 20th, 2018, Arrevus agreed to purchase fusidic acid, an antibiotic with more than 50 years clinical experience outside the United States that had been acquired by Melinta in a merger transaction with Cempra Pharmaceuticals (Cempra) and was under development by Cempra for the treatment of ABSSSI and refractory bone and joint infections. Fusidic acid is orally active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus strains.

Cempra successfully completed a phase 3 clinical trial in patients with ABSSSI demonstrating a tolerability profile and efficacy comparable to linezolid.

Further data presented at IDWeek 2018 showed that 60% of patients with refractory bone and joint infection were clinical successes after 6 months of oral fusidic acid treatment.

Fusidic acid received Orphan Drug Designation from the FDA for the treatment of prosthetic joint infection and also received Qualified Infectious Disease Product Designation under the Generating Antibiotic Incentives Now Act.

Arrevus is developing novel therapeutics for unmet medical needs in orphan indications. Arrevus also has a proprietary discovery platform, Insect Derived Anti-Infectives.
Details
Date Published: 08/02/2019
Target: fusidic acid
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Financing:
Status: Closed
Vendor: Melinta Therapeutics
Buyer: Arrevus Inc
Comment:
Fusidic acid received Orphan Drug Designation from the FDA for the treatment of prosthetic joint infection and also received Qualified Infectious Disease Product Designation under the Generating Antibiotic Incentives Now Act.

Options